Press Releases
Greedy Drug Company Loses In Court, Marking 6th Win For Medicare Patients
WASHINGTON, DC — Issuing a major win for seniors and patients struggling to afford life-saving medications, New Jersey District Court Judge Zahid Quraishi rejected Novo Nordisk’s challenge to the Inflation Reduction Act yesterday, ruling against the pharmaceutical giant’s attempt to ban Medicare from negotiating lower drug prices with manufacturers.
No matter how many times they’re told no, big pharma continues its unrelenting attack on seniors and patients struggling to afford life-saving medication by challenging the Biden-Harris administration’s historic Medicare negotiation program. They’re clogging the courts in an attempt to block seniors from saving billions of dollars a year to keep their own profits high, but their arguments are lost on a public that’s grown tired of paying exorbitant prices.”
Accountable.US Executive Director Tony Carrk
Yesterday’s ruling marks the sixth time a federal court has upheld Medicare’s power to negotiate drug prices. However, big pharma is intensifying its legal challenges to prevent the Biden-Harris administration from lowering Americans’ drug costs. Recent analysis from government watchdog Accountable.US found that several special interest groups, which filed amicus briefs on behalf of pharmaceutical giants AstraZeneca, Bristol Myers Squibb, and Janssen in the U.S. Court of Appeals for the Third Circuit, have collectively received nearly $4.8 million from PhRMA since 2019.
More on Pharma’s Fight to Keep Drug Costs High:
- Not So Neutral: Groups Filing Amicus Briefs Against New Medicare Rx Drug Program Took Nearly $4.8M from PhRMA
- Watchdog: Bristol Myers, J&J’s Greed Put in Check As Judge Rejects Latest Challenge to Biden Rx Medicare Negotiation Action
- REPORT: PhRMA Gave Half a Million to Election Denying Fringe Right Groups
